Literature DB >> 6228243

Concanavalin A induced suppressor cell activity and autorosette forming cells in chronic myeloid leukemia patients.

R Somasundaram, S H Advani, S G Gangal.   

Abstract

In the present paper attempts have been made to investigate suppressor cell activity in CML patients in first and subsequent remissions in order to study the relationship between suppressor cell activity and progression of the disease. For this purpose, the ability of Con A activated suppressor cells from peripheral blood of CML patients in 1st, 2nd and 3rd remission to suppress PHA response of autologous lymphocytes is investigated and compared with that of normal healthy donors. The ability of Con A activated cell population to form rosettes with autologous RBCs (ARFC) is also investigated. The results indicate that lymphocytes from CML patients in 1st (61.8 +/- 6.1%), 2nd (62.6 +/- 3.0%) and 3rd (55.3 +/- 4.8%) remissions show significantly high suppressor cell activity than normal healthy donors (36.5 +/- 1.9%) when activated with Con A. Similarly, generation of spontaneous suppressor cell activity was also higher in 1st (23.3 +/- 4.7%) and 2nd (25.3 +/- 4.2%) remission lymphocytes than controls (10.1 +/- 2.5%). In the 3rd remission however, the spontaneous suppressor cell activity (14.5 +/- 3.2%) was comparable to controls. Thus it appears that a higher suppressor cell precursor population is present in CML patients in remission. However, this could not be correlated with the progression of the disease. CML patients in 1st remission also revealed an increased percentage of ARFC which correlated with the suppressor cell function. The ARFC activity tested in a few patients in subsequent remissions was comparable with controls although functional suppressor activity was increased.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6228243      PMCID: PMC2011565          DOI: 10.1038/bjc.1983.267

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  18 in total

1.  Functional heterogeneity among the T-derived lymphocytes of the mouse. IV. Nature of spontaneously induced suppressor cells.

Authors:  F D Burns; P C Marrack; J W Kappler; C A Janeway
Journal:  J Immunol       Date:  1975-04       Impact factor: 5.422

2.  Human suppressor T cells induced by concanavalin A: suppressor T cells belong to distinctive T cell subclasses.

Authors:  T Sakane; I Green
Journal:  J Immunol       Date:  1977-09       Impact factor: 5.422

Review 3.  Suppressor cells: permitters and promoters of malignancy?

Authors:  D Naor
Journal:  Adv Cancer Res       Date:  1979       Impact factor: 6.242

Review 4.  The suppressor-cell network in cancer (second of two parts).

Authors:  S Broder; T A Waldmann
Journal:  N Engl J Med       Date:  1978-12-14       Impact factor: 91.245

5.  Evaluation of leukemia specific immunity in chronic myeloid leukemia.

Authors:  S G Gangal; C S Joshi; B P Gothoskar; M P Gollerkeri; S H Advani
Journal:  Haematologica       Date:  1977-10       Impact factor: 9.941

6.  Concomitant presence of tumor-specific cytotoxic and inhibitor lymphocytes in patients with osteogenic sarcoma.

Authors:  A Yu; H Watts; N Jaffe; R Parkman
Journal:  N Engl J Med       Date:  1977-07-21       Impact factor: 91.245

7.  Concanavalin A-inducible suppressor cells in regional lymph nodes of cancer patients.

Authors:  W J Catalona; T L Ratliff; R E McCool
Journal:  Cancer Res       Date:  1979-11       Impact factor: 12.701

8.  Suppressor cell activity after concanavalin A treatment of lymphocytes from normal donors.

Authors:  L Shou; S A Schwartz; R A Good
Journal:  J Exp Med       Date:  1976-05-01       Impact factor: 14.307

9.  Demonstration of cellular immunity in chronic myeloid leukaemia using leucocyte migration inhibition assay.

Authors:  S G Gangal; B P Gothoskar; C S Joshi; S H Advani
Journal:  Br J Cancer       Date:  1976-03       Impact factor: 7.640

10.  Cellular sensitization in chronic myeloid leukaemia patients to leukaemic blast antigens.

Authors:  S G Gangal; N K Damle; A G Khare; S H Advani
Journal:  Br J Cancer       Date:  1979-09       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.